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OBJECTIVES: Chronic hepatitis C (CHC) patients selected
for entry into treatment trials have been reported to have
impaired health-related quality of life (HRQOL). However,
these trials have an inherent selection bias, and HRQOL in
CHC patients may have been underestimated because of the
exclusion of patients with comorbid illness. The aim of this
study was to assess HRQOL in an unselected group of CHC
patients and to identify factors associated with impairment
in HRQOL.
METHODS: A total of 220 consecutive eligible CHC patients
were enrolled from a hepatology clinic. HRQOL was as-
sessed by the short form 36 (SF-36) and comorbid illnesses
were assessed by an interview.
RESULTS: CHC patients had significantly lower SF-36
scores in all subscales and in the summary scales when
compared to those of the healthy general population in the
United States (p  0.001). Compared to CHC patients
entering treatment trials, our patients had lower SF-36
scores on five subscales (p  0.001). The presence of
comorbid illness was the most important predictor of
HRQOL in CHC patients. However, CHC alone resulted in
significantly lower SF-36 scores in all subscales and sum-
mary scales (p  0.003) compared to those of the healthy
U.S. population. There was no correlation between SF-36
scores and history of i.v. drug use or dependence, alcohol
dependence, and serum aminotransferase levels.
CONCLUSIONS: We conclude that unselected CHC patients
presenting for medical evaluation have a reduced HRQOL,
which is lower than that reported for CHC patients entering
treatment trials. CHC alone is associated with significant
impairment in HRQOL, but the presence of comorbid illness
leads to further diminution in HRQOL. (Am J Gastroenterol
2001;96:2737–2744. © 2001 by Am. Coll. of Gastroenter-
ology)
INTRODUCTION
Approximately 1–2% of the U.S. population, or an esti-
mated 4 million Americans, are chronically infected with
hepatitis C (1). Although most chronic hepatitis C (CHC)
patients have few or no symptoms during the early stages of
their illness, several studies have reported impairment in
health-related quality of life (HRQOL) compared to healthy
individuals (2–7). Most studies have used an instrument
based on the short-form 36 (2–6) developed by the Medical
Outcomes Trust (8, 9). All but one of the published studies
on HRQOL in CHC patients have focused on patients se-
lected for enrollment into treatment trials (2, 4–6). In one
study, HRQOL was assessed in 642 treatment-naive CHC
patients who participated in a multicenter treatment trial.
Before treatment, the CHC patients had markedly impaired
quality of life compared to that of the healthy U.S. popula-
tion (2). During posttreatment follow-up, significant im-
provement in HRQOL was observed among the sustained
responders but not in the nonresponders or relapsers, sup-
porting a causal relation between viral replication and im-
pairment in HRQOL. However, sustained responders con-
tinued to have impaired HRQOL compared to healthy
individuals, suggesting that residual liver disease or factors
besides hepatitis C may be responsible for the persistent
impairment in HRQOL in these patients. These studies
clearly demonstrate a consistent and marked reduction in
HRQOL among CHC patients. However, the magnitude of
reduction in HRQOL associated with CHC may have been
underestimated because of selection bias, because patients
with psychiatric illness, polysubstance abuse or multiple
comorbid medical illnesses are usually excluded from treat-
ment trials. Serum aminotransferase (ALT) level (2–6),
presence of cirrhosis on liver biopsy (3, 6, 10), and viral
factors (2, 6) have not been shown to correlate with HRQOL
in CHC patients.
Among the published studies on HRQOL in CHC pa-
tients, only one was conducted outside the context of a
treatment trial (3). This study found that CHC patients had
not only lower HRQOL scores than those of healthy con-
trols, but also lower scores than those of chronic hepatitis B
patients (N  30) with similar severity of liver disease. We
hypothesize that unselected CHC patients have more
marked impairment in HRQOL than that reported in patients
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enrolled in clinical treatment trials. We further hypothesize
that although CHC itself may result in impaired HRQOL,
extrahepatic factors such as history of drug or alcohol abuse,
as well as concomitant medical or psychiatric illness may be
important determinants of HRQOL in CHC patients (11).
The aims of our study were to assess HRQOL in consecutive
CHC patients attending our General Hepatology Clinic and




Consecutive eligible CHC patients attending the General
Hepatology Clinic at the University of Michigan Hospital
during the 7-month period between October, 1999, and
May, 2000, were invited to participate in the study. Inclu-
sion criteria were detectable hepatitis C antibody or hepatitis
C virus RNA (HCV RNA), with or without elevation in
serum ALT level. Both men and women, of all races, be-
tween the ages of 15 and 70 yr were included. Patients who
were receiving or had received treatment with interferon
alone or in combination with ribavirin during the past 3
months were excluded, as were sustained responders to
previous therapy. Patients with decompensated liver dis-
ease, coinfection with hepatitis B or HIV, other causes of
liver disease, malignancies in the past 1 yr, life-threatening
medical problems, or marrow/organ transplantations were
also excluded. The study was approved by the institutional
review board at the University of Michigan Hospital, and
written informed consent was obtained from each patient.
Potentially eligible participants were identified 2 wk be-
fore their clinic appointment by screening the physicians’
schedules, referral letters, and computerized medical
records. A letter of invitation was mailed to eligible patients
together with a copy of the consent form. The patients
received up to two follow-up phone calls 1 wk later to
explain the study and to inquire about their interest in
participation. Interested individuals were scheduled to com-
plete a confidential survey in a private area before their
physician appointment. Medical records and laboratory test
results were reviewed after the clinic visit to confirm par-
ticipant eligibility.
Data Collection
A 67-item, self-administered survey with the SF-36 embed-
ded within it was used to collect data on HRQOL, demo-
graphics, risk factors for HCV infection, patient knowledge
about transmission and prognosis of CHC, and alcohol and
drug use history. The SF-36 is a self-administered generic
instrument that assesses a patient’s QOL along eight sub-
scales and two summary scales. The subscales include phys-
ical functioning (PF), role-physical (RP), role-emotional
(RE), vitality (VT), mental health (MH), social functioning
(SF), general health (GH), and bodily pain (BP). The sum-
mary scales consist of physical health (PCS) and mental
health (MCS). The SF-36 subscale and summary scores
range from 0 to 100, with higher scores reflecting better
HRQOL.
Patients who reported a history of i.v. drug use or a
history of regular alcohol consumption (defined as two
drinks daily for 3 months) were asked if they ever con-
sidered themselves to be dependent on drugs or alcohol.
Drug and alcohol dependence was further assessed by in-
quiring about the duration of use and the need for counseling
or rehabilitation. History of current comorbid medical or
psychiatric illness was obtained during a brief interview and
corroborated with physicians’ notes and medication lists.
Completion of the survey and medical interview required an
average of 45 min. Reports of liver biopsies performed
within the last 2 yr were reviewed for the presence or
absence of cirrhosis. Serum ALT levels within 3 months of
the study visit were recorded.
Data Analyses
Descriptive statistics were calculated and reported as
means  SD unless indicated otherwise. SF-36 scores were
calculated using SAS software (SAS, Cary, NC). Statistical
analysis was performed using SPSS for Windows 1997
(SPSS, Chicago, IL). Normative population data for SF-36
scores were obtained through the Medical Outcomes Trust
(12, 13). These data were based on a sample (N  2474) of
noninstitutionalized members of the general U.S. popula-
tion, aged 18–94 yr, gathered from October through De-
cember, 1990. SF-36 subscale and summary scores were
compared to healthy and general U.S. population controls
using analysis of variance. Univariate analysis of associa-
tions among clinical variables of interest and the 10 sub-
scales and summary scores of the SF-36 were determined
using correlations, 2, analysis of variance, and Kruskal-
Wallis tests. Because multiple comparisons were conducted,
a p value of 0.01 was considered statistically significant.
RESULTS
Characteristics of the Study Population
A total of 674 patients with CHC attended the General
Hepatology Clinic at the University of Michigan Hospital
during the 7-month study period. Of these, 268 patients were
ineligible for the study: 136 patients had decompensated
liver disease; 68 were either currently receiving or had
received antiviral therapy within the past 3 months; 12 were
sustained responders to previous antiviral therapy; and 52
met other exclusion criteria.
Of the 406 CHC eligible patients, 220 (54%) patients
were enrolled in the study. The remaining 186 patients were
unable to participate, primarily because of time constraints
during their clinic appointments.
A total of 139 (63%) participants were men (Table 1).
The mean age was 46.6  7.9 yr. In all, 81% were Cauca-
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sian and 9% African-American. Of the patients, 62% had
completed high school and 29% were college graduates.
When the study population was compared to eligible non-
participants, there was no difference in gender; however, the
study population was slightly older and more likely to be
Caucasian (Table 1).
Serum ALT was within the normal range in 45 (20%)
patients. Of the 115 (52%) patients who had liver biopsies
within the last 2 yr, 40 (35%) had cirrhosis.
Comorbid Illness
One or more comorbid medical or psychiatric illnesses was
present in 157 (71%) patients (Table 2); 114 patients
(51.8%) had medical illness only, 36 (16.4%) had both
medical and psychiatric illnesses, and seven (3.2%) had
psychiatric illness only. The common medical and psychi-
atric diagnoses are listed in Table 2. Among the patients
with medical comorbid illness only, 59 (52%), 32 (28%),
and 23 (20%) patients had 1, 2, and 3 medical diagnoses,
Table 1. Characteristics of the Study Population
CHC Study Group Nonparticipants p
No. of patients 220 186
Age (yr)
Mean  SD 46.6  7.9 44.8  8.4 0.03
Range 19–69 18–70
Gender ns
Male 139 (63%) 119 (64%)
Female 81 (37%) 67 (36%)
Race 0.03
Caucasian 179 (80.9%) 129 (69.4%)
African-American 20 (9.1%) 26 (14%)
Native American 10 (4.5%)
Hispanic 5 (2.3%)
Asian 1 (0.5%)
Unknown/other 5 (2.3%) 31 (16.6%)
Educational level
Some high school 21 (9.6%)
High school graduate 136 (61.8%)
College graduate 63 (28.6%)
Marital status






Working (full/part time) 152 (69%)






Mean  SD 115  89 IU/L




No biopsy data in last 2 yr 105 (47.7%)
Treatment
Treatment naive 168 (76.3%)
No sustained response to previous Rx 52 (23.6%)
Intravenous drug use
Yes 111 (50.4%)
Drug dependence 67 (31%)




Alcohol dependence 47 (21.7%)
Alcohol rehabilitation 54 (24.5%)
No 101 (45.9%)
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respectively. Of the patients with combined medical and
psychiatric illnesses 12 (33%), 10 (28%), and 14 (39%)
patients had 1, 2, and 3 medical diagnoses, respectively.
The mean number of comorbid medical illness in these two
groups was similar (1.8 vs 2.2/patient, ns).
Substance Abuse
A total of 111 (50%) patients reported a history of i.v. drug
use, 67 (31%) considered themselves to be dependent on
recreational drugs at some stage of their lives, and 61
(27.7%) reported prior counseling or rehabilitation for drug
abuse (Table 1). In addition, 119 (54%) patients reported a
history of regular alcohol consumption, 47 (22%) consid-
ered themselves to have been dependent on alcohol at some
stage of their lives, and 54 (24.5%) reported prior counsel-
ing or rehabilitation for alcohol abuse (Table 1).
HRQOL in CHC Patients
The mean SF-36 scores in our CHC patients were signifi-
cantly lower than those of the general U.S. as well as the
healthy U.S. population in all eight subscales and the two
summary scales (p  0.001) (Fig. 1). Because there was a
preponderance of male participants, comparison with the
general U.S. population was repeated after controlling for
gender. The SF-36 scores in our CHC patients remained
significantly lower than age and gender matched general
U.S. population (p  0.001).
To determine whether HRQOL scores for our CHC pa-
tients were lower than for CHC patients selected for treat-
ment trials, we compared the SF-36 scores of our patients
with the pretreatment scores from the largest published
study of HRQOL in CHC patients enrolled in a treatment
trial (2). The SF-36 scores in our patients were lower in all
eight subscales, the difference being significant in five sub-
scales (PF, BP, GH, RE, and MH, p  0.001) (Fig. 2).
Similar findings were observed when our results were com-
Table 2. List of Common Comorbid Illnesses








Cardiovascular diseases 16 (7.3)
Other pulmonary diseases 3 (1.3)
Other musculoskeletal disorders 27 (12.3)
Other gastrointestinal diseases 25 (11.4)
Neurologic diseases 14 (3.6)
Renal diseases 6 (2.7)




Miscellaneous diagnoses 7 (3.2)
Figure 1. Health-related quality of life in chronic hepatitis C patients versus healthy and general U.S. population.
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pared to the pretreatment scores of CHC patients participat-
ing in a retreatment trial for relapsers (data not shown) (6).
To determine whether HRQOL scores for our CHC pa-
tients were lower than for other CHC patients who were not
participating in treatment trials, we compared the SF-36
scores of our patients with those reported by Foster et al. (3).
The SF-36 scores in our patients were lower in two sub-
scales (PF, p  0.004; BP, p  0.001), higher in two
subscales (SF, p  0.001; RE, p  0.003) and similar in the
remaining four subscales (Fig. 2).
HRQOL and Comorbid Illness
Compared to the healthy US population, the 63 CHC pa-
tients with no comorbid medical or psychiatric illness had
significantly lower SF-36 scores in all subscales and sum-
mary scales (p  0.003) (Fig. 3). The SF-36 scores were
more markedly reduced among the 157 CHC patients with
comorbid illness (p  0.001).
Among the patients with comorbid illness, HRQOL was
more profoundly affected in patients who had a psychiatric
diagnosis. Compared to CHC patients with no comorbid
illness, the presence of a psychiatric diagnosis alone resulted
in significant reductions in SF-36 scores in four subscales
and one summary scale, whereas the presence of a combi-
nation of psychiatric and medical illnesses resulted in sig-
nificant reductions in SF 36-scores in all subscales and both
summary scales (Fig. 3). Comorbid medical illness alone
had less impact on the SF-36 scores in patients with CHC,
with no appreciable change in SF-36 scores in patients with
one comorbid medical illness, as well as significant reduc-
tions in SF-36 scores in only two subscales and the physical
summary scale in patients with two comorbid medical ill-
nesses. Patients with three or more comorbid medical ill-
nesses had greater reductions in HRQOL, with significant
reduction in SF-36 scores in six subscales and the physical
summary scale compared to CHC patients with no comorbid
illness.
HRQOL and Demographic Factors
There was no correlation between age and race with SF-36
scores in our study population. Women tended to have lower
SF-36 scores compared to men, but a significant difference
was noted only in selected physical subscales (Table 3).
Similarly, level of education and marital status demon-
strated weak correlations with a few SF-36 subscales in the
expected direction (i.e., individuals with a higher level of
education and married individuals had higher SF-36 scores)
(Table 3).
HRQOL and Liver Disease Parameters
There was no significant correlation between any SF-36
subscales or summary scores and the liver disease parame-
ters of serum ALT level or the presence of cirrhosis on liver
biopsy. CHC patients who were nonresponders to previous
Figure 2. Health-related quality of life in chronic hepatitis C patients versus healthy U.S. population and CHC patients in two published
reports.
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treatment had SF-36 scores similar to those of treatment-
naive patients.
HRQOL and History of Substance Abuse
There was no significant correlation between SF-36 sub-
scale or summary scores and history of drug or alcohol use
or dependence.
DISCUSSION
Similar to other published reports, we found that the
HRQOL in our CHC patients was significantly impaired
when compared to U.S. healthy and general populations.
Our study also showed that the HRQOL scores in unselected
CHC patients were significantly lower than CHC patients
enrolled in treatment trials (2). These findings suggest that
previous studies may have underestimated the extent of
impairment in HRQOL in CHC patients. We acknowledge
that our study was performed in a different clinical setting
and that the tools we used to assess HRQOL were not
identical to that in the study by Bonkovsky et al. (2). In
addition, comparisons were made based on overall results of
the two groups of patients and not on actual data. These
methodological problems may bias our conclusions. Never-
theless, both studies used SF-36 as the core instrument to
assess HRQOL. Moreover, comparisons of the actual data in
this study with those of our previous study of 107 patients
enrolled in a retreatment trial (11) also showed that patients
in the current study had significantly lower subscale and
summary scores. The SF-36 scores in our patients were
comparable to those reported in another, unselected CHC
patient population (3), lending support to our hypothesis that
HRQOL in the general pool of CHC patients is lower than
in CHC patients who qualify for entry into clinical trials.
We acknowledge that our results may not be generalized
to all CHC patients because of the enrollment rate of 54%
and selection of patients referred to a liver clinic. The design
of our study required an extra 45 min in addition to the clinic
visit. Although time constraint was the major reason for
Figure 3. Health-related quality of life in chronic hepatitis C patients with no comorbid medical illness versus CHC patients with comorbid
medical or psychiatric illness, and healthy U.S. population.
Table 3. Univariate Analysis Comparing HRQOL and Demographic Characteristics
SF-36 Subscales and Summary Scales
PF RP BP GH VT SF RE MH PCS MCS
Age ns ns ns ns ns ns ns ns ns 0.006
Race ns ns ns ns ns ns ns ns ns ns
Gender 0.001 ns 0.006 0.001 0.001 0.005 ns ns 0.001 ns
Education 0.006 ns .001 0.01 ns 0.009 ns ns 0.001 ns
Marital status 0.005 ns 0.003 0.008 ns .001 ns 0.006 0.006 ns
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study refusal, it was our belief that data provided by the
patient in a private environment with no influence from
family or friends are more reliable than those from a ques-
tionnaire completed and mailed from home. Our study de-
sign also allowed us to have a more accurate and complete
assessment of comorbid illness. Compared to the eligible
CHC patients who did not participate in this study, our
patients were similar in gender, with a difference in mean
age of only 1.8 yr. The higher proportion of Caucasians in
our study compared to the patients who declined to partic-
ipate may have created a small bias in our results. However,
our data showed that there was no correlation between
HRQOL and race or age of the participants.
As in our previous study of patients with IFN refractory
CHC (11), we found that the presence of comorbid illness
was the most important predictor of HRQOL in CHC pa-
tients. However, CHC patients without comorbid illness
also had significant impairment in SF-36 scores when com-
pared to healthy individuals, indicating that CHC alone is
sufficient to cause reduction in HRQOL. Our study demon-
strated that comorbid illness in CHC patients led to further
reduction in HRQOL. Moreover, a psychiatric diagnosis
alone was associated with more marked decrease in SF-36
scores compared to those of medical illness. The impact of
comorbid illness, in particular psychiatric illness, on
HRQOL in CHC patients may account for the lower SF-36
scores in our patients compared to those selected for treat-
ment trials as patients with psychiatric illness or multiple
comorbid medical illness are usually excluded from treat-
ment trials. We acknowledge that the impact of comorbid
psychiatric illness alone on HRQOL in CHC patients should
be further studied, as there were only seven patients in this
group.
In this study, women tended to have lower SF-36 scores,
a finding that has been consistently reported even among
healthy subjects (12) and in those with other chronic dis-
eases (14). We also found weak associations between
HRQOL and level of education as well as marital status.
These associations are probably nonspecific and may reflect
better socioeconomic status among patients with higher
levels of education and less emotional distress among those
who are married.
Contrary to our hypothesis, a history of drug use or
dependence was not associated with a more marked dimi-
nution in HRQOL in our CHC patients. This is different
from the study by Foster et al., which found that patients
with a history of i.v. drug use had lower SF-36 scores. This
finding was unexpected, as previous studies have shown that
subjects with a history of i.v. drug use have psychological
disturbances that may lead to a reduction in HRQOL (15,
16). The reason for the lack of association in our study may
be related to the fact that the history of i.v. drug use was
remote in most patients. We also found no association
between a history of alcohol use or dependence and HRQOL
in our CHC patients.
As in other studies (2–7, 10), the liver disease parameters
of serum ALT or presence of cirrhosis on liver biopsy did
not correlate with SF-36 scores in our CHC patients. We
acknowledge that only half of our patients had liver biopsies
in the last 2 yr, so the impact of compensated cirrhosis on
HRQOL in CHC patients cannot be accurately assessed.
Other studies showed that viral factors were also not asso-
ciated with SF-36 scores in CHC patients. Thus, the reasons
for diminished HRQOL in CHC patients with no comorbid
illness remain unclear.
In summary, we have clearly demonstrated that HRQOL
is significantly impaired in CHC patients, and that the re-
duction in HRQOL is more marked in unselected CHC
patients compared to CHC patients who are selected for
entry into treatment trials. The presence of comorbid illness
is the most important predictor of HRQOL in CHC patients,
but CHC alone is sufficient to result in significant diminu-
tion in HRQOL compared to that of healthy individuals.
These findings underscore the health burden of CHC even in
ostensibly asymptomatic patients, and highlight the need to
develop more effective and better-tolerated treatments that
can benefit more patients with CHC. Our results also em-
phasize the importance of managing other comorbid illness
in CHC patients, as well as the need to conduct research into
the mechanisms of impaired HRQOL among patients with
CHC alone.
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